Pulmonary herpes simplex virus and cytomegalovirus in patients with acute respiratory distress syndrome related to COVID-19
Leonoor S Boers,Frank van Someren Gréve,Jarne M van Hattem,Justin de Brabander,Tom Zwaan,Hugo van Willigen,Marion Cornelissen,Menno de Jong,Tom van der Poll,JanWillem Duitman,Janke Schinkel,Lieuwe D J Bos,and the OPPORTUNE consortium, the Amsterdam UMC COVID study group, the ArtDECO consortium,Paul E Verweij,Simone J C F M Moorlag,Frank L van de Veerdonk,Frank van Someren Grevé,Jeroen J A van Kampen,Joost Wauters,Katrien Lagrou,Simon Feys,Jannes Heylen,Michiel van Agtmael,Anne Geke Algera,Brent Appelman,Floor van Baarle,Diederik van de Beek,Martijn Beudel,Harm Jan Bogaard,Lieuwe Bos,Michela Botta,Godelieve de Bree,Matthijs C Brouwer,Sanne de Bruin,Marianna Bugiani,Esther Bulle,David T P Buis,Osoul Chouchane,Alex Cloherty,Mirjam Dijkstra,Dave A Dongelmans,Romein W G Dujardin,Paul Elbers,Lucas Fleuren,Suzanne Geerlings,Theo Geijtenbeek,Armand Girbes,Bram Goorhuis,Martin P Grobusch,Laura Hagens,Jorg Hamann,Vanessa Harris,Robert Hemke,Sabine M Hermans,Leo Heunks,Markus Hollmann,Janneke Horn,Joppe W Hovius,Menno D de Jong,Rutger Koning,Endry H T Lim,Niels van Mourik,Jeaninne Nellen,Esther J Nossent,Frederique Paulus,Edgar Peters,Dan A I Piña-Fuentes,Bennedikt Preckel,Jorinde Raasveld,Tom Reijnders,Maurits C F J de Rotte,Michiel Schinkel,Marcus J Schultz,Femke A P Schrauwen,Alex Schuurman,Jaap Schuurmans,Kim Sigaloff,Marleen A Slim,Patrick Smeele,Marry Smit,Cornelis S Stijnis,Willemke Stilma,Charlotte Teunissen,Patrick Thoral,Anissa M Tsonas,Pieter R Tuinman,Marc van der Valk,Denise Veelo,Alexander P J Vlaar,Carolien Volleman,Heder de Vries,Lonneke A Vught,Michèle van Vugt,W Joost Wiersinga,Dorien Wouters,A H Zwinderman,Matthijs C Brouwer E J Nossent,J W Duitman,A Saris,H de Vries,L J Meijboom,L D J Bos,S G Blok,A R Schuurman,T D Y Reijnders,J J Garcia Vallejo,H Bontkes,A P J Vlaar,W J Wiersinga,R Lutter,T van der Poll,H J Bogaard,L Heunks,S Zhang,R F J Kullberg,J de Brabander,L S Boers
DOI: https://doi.org/10.1007/s00134-024-07529-x
Abstract:Purpose: Human herpesviruses, particularly cytomegalovirus (CMV) and herpes simplex virus (HSV), frequently reactivate in critically ill patients, including those with acute respiratory distress syndrome (ARDS) related to coronavirus disease 2019 (COVID-19). The clinical interpretation of pulmonary herpesvirus reactivation is challenging and there is ongoing debate about its association with mortality and benefit of antiviral medication. We aimed to quantify the incidence and pathogenicity of pulmonary CMV and HSV reactivations in critically ill COVID-19 patients. Methods: Mechanically ventilated COVID-19 patients seropositive for CMV or HSV were included in this observational cohort study. Diagnostic bronchoscopy with bronchoalveolar lavage was performed routinely and analyzed for alveolar viral loads and inflammatory biomarkers. Utilizing joint modeling, we explored the dynamic association between viral load trajectories over time and mortality. We explored alveolar inflammatory biomarker dynamics between reactivated and non-reactivated patients. Results: Pulmonary reactivation (> 104 copies/ml) of CMV occurred in 6% of CMV-seropositive patients (9/156), and pulmonary reactivation of HSV in 37% of HSV-seropositive patients (63/172). HSV viral load dynamics prior to or without antiviral treatment were associated with increased 90-day mortality (hazard ratio [HR] 1.24, 95% confidence interval [CI] 1.04-1.47). The alveolar concentration of several inflammatory biomarkers increased with HSV reactivation, including interleukin (IL)-6, IL-1β, granulocyte colony stimulating factor (G-CSF), and tumor necrosis factor (TNF). Conclusion: In mechanically ventilated COVID-19 patients, HSV reactivations are common, while CMV reactivations were rare. HSV viral load dynamics prior to or without antiviral treatment are associated with mortality. Alveolar inflammation is elevated after HSV reactivation.